SCHEMBL5083002

SCHEMBL5083002

CCC(O[Si](C)(C)C(C)(C)C)(C(C)O)n1cnc2c(N)ncnc21

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PI4KA P42356 5/20 0.53
PI4K2B Q8TCG2 5/20 0.53
PI4K2A Q9BTU6 5/20 0.53
PI4KB Q9UBF8 5/20 0.53
ADORA2A P29274 6/20 0.45
ADORA1 P30542 5/20 0.45
ADORA2B P29275 3/20 0.43
ADA P00813 4/20 0.41
PDE2A O00408 3/20 0.41
CYP3A4 P08684 2/20 0.41
PDE4A P27815 1/20 0.41
PDE4B Q07343 1/20 0.41
PDE4C Q08493 1/20 0.41
PDE4D Q08499 1/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
CYP1A2 P05177 1/20 0.41
ALOX15 P16050 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HSD17B10 Q99714 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5080093 0.76 PI4KA (0.63) PI4KAPI4K2BPI4K2API4KBADORA2A
SCHEMBL5083011 0.75 PI4KA (0.55) PI4KAPI4K2BPI4K2API4KBADORA2A
SCHEMBL22666249 0.75 PI4KA (0.74) PI4KAPI4K2BPI4K2API4KBADORA2A
SCHEMBL5086075 0.73 CYP3A4 (0.46) PI4KAPI4K2BPI4K2API4KBADORA2A
SCHEMBL20253540 0.72 PI4KA (0.74) PI4KAPI4K2BPI4K2API4KBADORA2A
SCHEMBL18680909 0.71 PI4KA (0.53) PI4KAPI4K2BPI4K2API4KBADORA2A
SCHEMBL21118446 0.71 PI4KA (0.67) PI4KAPI4K2BPI4K2API4KBADORA2A
SCHEMBL22020877 0.70 PI4KA (0.67) PI4KAPI4K2BPI4K2API4KBADORA2A
SCHEMBL5086024 0.70 PI4KA (0.48) PI4KAPI4K2BPI4K2API4KBADORA2A
SCHEMBL11476962 0.69 PI4KA (0.75) PI4KAPI4K2BPI4K2API4KBADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7388002-B2 Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases BIOCRYST PHARMACEUTICALS, INC. (US) 2008-06-17 US disclosed
US-20060122391-A1 Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases BIOCRYST PHARMACEUTICALS, INC. (US) 2006-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122391-A1 Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases POLR2H, NSUN2, POLR2E PI4KA 2684/4885PI4K2B 1893/4885PI4K2A 2678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.